Oncologists Charge More Than Other Specialties For Same Drugs, Study Finds
Executive Summary
Oncologists charge at least 50% more for Lupron and Aranesp than do urologists or nephrologists, researchers with Johns Hopkins and Memorial Sloan Kettering found.
You may also be interested in...
Why Is Drug Pricing Higher In US? Study Takes Aim At R&D Argument
Amgen, Biogen, Pfizer and Teva generated more than twice their global R&D budgets with higher pricing in the US compared to Western Europe and Canada, researchers at Memorial Sloan Kettering found.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.
Medicare Reimbursement For Part B Drugs Is 48% Above 340B Prices To Hospitals, MedPAC Finds
New study updates past commission analyses and highlights the significant margin between Medicare payments for drugs and the prices paid by 340B-eligible providers.